P03-100 - Experience of Using High and Low Doses of Cerebrolizin at Patients with Rezidiual Schizophrenia

Introduction Using high and low doses of cerebrolizin at patients with rezidiual schizophrenia Objectives The purpose of the present research was comparative clinical-pharmacological studying with estimation cognitive functions of high and low doses Cerebrolysinum at patients with residual schizophrenia. Methods In total 37 patients the majority from which were male (89%), at the age of 50-55 years have been included in research. Duration of disease mainly 5-10 years. All patients had physical inability of 2 groups on mental disease, accepted neuroleptics throughout all illness, and last year - in invariable doses. Patients in any order were distributed on three therapeutic groups: 1. high doses “Cerebrolysinum” (10 ml) - 17. 2. low doses “Cerebrolysinum” (1 ml) - 10. 3. not accepting “Cerebrolysinum” - 10. Duration of research - 4 weeks. Results By the end of therapy at 10% of patients of 1st group the expressed improvement, at 73% - substantial improvement, and only in 17% cases - minor improvement. In 2nd group of the patients accepting low doses “Cerebrolysinum”, efficiency of therapy was essentially more low: at 27% of patients minor improvement, at 69% - minimum has been reached, and in 4% cases of positive dynamics by the therapy end wasn’t observed. In control group (3rd) at 90% of patients by the end of therapy the condition remains without changes, and 10% - had insignificant deterioration. Conclusion Using high doses of “Cerebrolysinum” gives high results in treatment of residual schizophrenia.

Hali tarjima qilinmagan